David Kirske - 30 Jun 2021 Form 4 Insider Report for CTI BIOPHARMA CORP

Role: EVP, Chief Financial Officer
Signature: /s/ David Kirske
Issuer symbol: N/A
Transactions as of: 30 Jun 2021
Net transactions value: +$7,617
Form type: 4
Filing time: 11 Mar 2022, 18:41:18 UTC
Next filing: 16 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTIC	Common Stock	Award	$3,787	+1,782	+47%	$2.12	5,580	30 Jun 2021	Direct	F1
transaction	CTIC	Common Stock	Award	$3,830	+1,817	+33%	$2.11	7,397	31 Dec 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTIC	Stock Option (right to buy)	Award	$0	+280,000		$0.000000	280,000	09 Mar 2022	Common Stock	280,000	$4.49	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.
F2	The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates.